Strategic Pivot and Operational Performance
-
Performance in Q1 was driven by a 55% revenue increase following the strategic sale of Bressner, which management believes unlocks shareholder value and sharpens focus on high-margin edge AI opportunities.
-
Growth was attributed to increased shipments for the P-8 aircraft and prototype deliveries for U.S. Army enhanced vision systems, alongside rising demand from medical imaging OEMs for liquid-cooled server platforms.
-
Management reported a record book-to-bill ratio of 1.8, with $15 million in new bookings nearly equaling the total bookings generated for the entirety of 2023.
-
The average order size has increased nearly 3x since 2023, reflecting a shift toward larger, more programmatic, and multiyear deployments across both defense and commercial sectors.
-
The opportunity pipeline has expanded significantly from a previous estimate of $1 billion, driven by a deliberate effort to align with applications that scale across both markets.
-
Customer-funded development increased 145% year-over-year, which management views as a critical strategy to embed OSS early in the life cycle of next-generation defense and commercial platforms.
2026 Outlook and Strategic Assumptions
-
Management reaffirmed 2026 revenue growth guidance of 20% to 25%, assuming a planned ramp in the second half of the year as development programs transition into production.
-
Gross margins are expected to normalize to approximately 40% for the full year, reflecting a mix of product shipments and an increasing contribution from customer-funded development.
-
Guidance assumes potential timing impacts from supply chain constraints, specifically longer lead times for memory components and CPUs which remain the critical path for deliveries.
-
The company expects to generate positive EBITDA and adjusted EBITDA while continuing to invest in sales expansion and customer support resources.
-
Management indicated that the strengthened balance sheet, with $34.4 million in cash and no debt, provides flexibility for selective strategic acquisitions to enhance technology capabilities.
Structural Changes and Risk Factors
-
The sale of the Bressner subsidiary in December 2025 for $22.4 million resulted in its historical results being reclassified as discontinued operations.
-
Supply chain volatility has moderated but plateaued at higher pricing levels; management intends to pass these increased costs to customers rather than absorbing them.
-
While defense budgets for 2026 are passed, management noted a potential risk of slight delays in award timing due to the redirection of logistics and material for Middle East operations.
-
The company introduced a next-generation PCIe Gen 6 product portfolio to address increasing bandwidth requirements for AI and machine learning workloads at the edge.
Q&A Session Insights
Supply chain constraints and memory component availability
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Memory is the primary constraint with extended lead times and higher pricing, though volatility has moderated compared to three months ago.
-
Management is implementing risk mitigation actions to manage delivery timing and has been successful in passing price increases to customers.
Impact of Middle East conflicts on defense bookings
-
No significant impact on 2026 bookings has been observed yet as budgets were already passed, though some award timing delays are anticipated.
-
Management believes these conflicts may eventually create new opportunities for high-performance compute solutions to support specific sensor and software applications.
Timeline for autonomous robotics and aerospace production
-
The commercial robotics program for construction and mining is expected to transition to production in 2026.
-
The commercial aerospace passenger cabin system has already transitioned into production with deliveries starting in 2026.
Status of autonomous maritime and medical imaging programs
-
Autonomous maritime systems are currently under test and evaluation, with production orders expected later in 2026.
-
The medical imaging program is seeing a production ramp, and management is exploring tech refresh opportunities to enhance compute performance.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
